Interactions between the T cell co-receptors CD4 or CD8 and the kinase Lck safeguard T cell activation by low-affinity ligands. Meanwhile, ‘free’ Lck — which cannot bind co-receptors — elicits efficient anti-viral and anti-tumor responses by CD8+ T cells in vivo.